NCT06056297Phase 3Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Study sponsor: X4 Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-09Estimated
Enrollment · participants176Estimated
Source updated2026-11-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview